Eagle Health Investments LP Lowers Stock Holdings in Natera, Inc. $NTRA

Eagle Health Investments LP lowered its position in shares of Natera, Inc. (NASDAQ:NTRA) by 10.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 183,264 shares of the medical research company’s stock after selling 20,400 shares during the period. Natera accounts for approximately 9.2% of Eagle Health Investments LP’s investment portfolio, making the stock its 3rd biggest holding. Eagle Health Investments LP’s holdings in Natera were worth $41,984,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in NTRA. Horizon Investments LLC bought a new position in Natera during the 3rd quarter worth $32,000. Flagship Harbor Advisors LLC acquired a new position in Natera in the 4th quarter valued at $41,000. Sound Income Strategies LLC raised its holdings in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 45 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in Natera in the 4th quarter valued at $62,000. Finally, AXS Investments LLC acquired a new position in Natera in the 3rd quarter valued at $69,000. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NTRA. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Robert W. Baird set a $265.00 price objective on Natera in a report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price objective on shares of Natera in a report on Tuesday, May 12th. Finally, Wells Fargo & Company lifted their price objective on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $256.60.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 902 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $206.16, for a total value of $185,956.32. Following the completion of the transaction, the chief executive officer owned 149,867 shares of the company’s stock, valued at $30,896,580.72. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,405 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the completion of the transaction, the insider owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This trade represents a 2.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 38,266 shares of company stock worth $7,747,808. Insiders own 5.63% of the company’s stock.

Natera Stock Performance

Shares of NTRA stock opened at $204.92 on Thursday. The stock’s fifty day moving average price is $200.69 and its two-hundred day moving average price is $215.38. The company has a market cap of $29.35 billion, a PE ratio of -125.72 and a beta of 1.57. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The firm had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter last year, the business posted ($0.41) EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.